Patrick Hwu, President and CEO of Moffitt Cancer Center, shared a post on LinkedIn about a paper by Yu-Chan Chih et al. published in Nature Communications:
“How can we treat solid tumor such as glioblastoma with T-cell therapy?
Immunotherapy using T cells transduced to express tumor-specific T cell receptors (TCR) is now an FDA-approved strategy for some patients with sarcoma. Applying this approach to other cancer types requires the identification of TCRs capable of specifically recognizing these cancers.
In a recent report, investigators describe a TCR that recognizes glioblastoma, and importantly glioblastoma stem cells.
Their preclinical models lay the groundwork for a clinical trial for HLA-A2 positive glioblastoma patients.”
“Vaccine-induced T cell receptor T cell therapy targeting a glioblastoma stemness antigen”
Authors: Yu-Chan Chih et al.
More posts featuring Patrick Hwu.
